TALZENNA® first PARP inhibitor to demonstrate clinical benefit in combination with XTANDI® in metastatic castration-resistant prostate cancer (mCRPC)
Study achieves primary endpoint of radiographic progression-free survival
Robust, highly consistent efficacy demonstrated in mCRPC both with or without homologous recombination repair gene mutations
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.